BioPharm America™ 2012 Program is Full-to-Brimming with Top Life Science CEOs

BioPharm America™ 2012 Program is Full-to-Brimming with Top Life Science CEOs

<0> MassBioSarah MacDonald+1-617-674-5115orEBD GroupErin Righetti+1-760-930-0500 </0>

BioPharm America™, to be held September 19–21, 2012 in Boston, MA has an unprecedented program line-up featuring top CEOs for what will be the most influential US life science partnering event of 2012. EBD Group, the leading partnering firm for the life science industry, will hold the annual event at the Westin Boston Waterfront in collaboration with the Massachusetts Biotechnology Council (MassBio).

“BioPharm America is well-established as the leading North American life science partnering event,” said , President of EBD Group. “The deals that have previously been made at this event have had an incredibly positive impact on the year-end prospectus for our attending biotech and pharma executives. They count on us to bring them face-to-face with the best the industry has to offer.”

“The landscape for biopharma companies is changing with new laws and a greater focus on patient needs,” said CEO of Genzyme, a Sanofi company. “What worked in the past to make Genzyme a global biotechnology leader based in Massachusetts, may not work today. I look forward to sharing thoughts on innovation and partnering opportunities with others at BioPharm America.”

Wednesday’s opening plenary session “Who is the best player in the value chain?” will be moderated by of Flagship Ventures with speakers of Epizyme; of AstraZeneca; of Takeda Pharmaceuticals; and of Shire HGT.

“This topic will ensure a lively discussion,” said, Epizyme’s President and CEO. “Biotechs have demonstrated the ability to deliver innovative research, but we have often relied on pharma partners to bring those discoveries through clinical development and beyond. Emerging strategies, like the creation of personalized therapeutics for patients with genetically defined diseases, now enable innovation in business models as well. It will be interesting to explore the potential for biotechs to once again drive their products through development and to the market.”

Thursday’s keynote panel “From start-up to commercial company and the challenges in between: Could we do it again today?” will be moderated by industry expert of BioCentury. Speakers include of Organogenesis; of Genzyme, a Sanofi company; and of Alkermes.

“Partnering is one of the most critical tools to offset the cost associated with R&D. We will discuss innovation in pharmaceutical development and how collaborations have changed the way we do business,” said , CEO of Alkermes.

Adding suspenseful fun to the program, Wednesday’s spotlight panel “Let's make a deal because ‘Biotech has talent’” will give delegates in the audience 30 seconds to pitch their company, product, technology or service to a star-studded panel of judges representing big pharma. Moderator of MacDougall Biomedical Communications will call upon delegates to present to the jury made up of of AstraZeneca; of Novo Nordisk; of Ironwood Pharmaceuticals; of Shire; and of Amgen. The first and second place winners will receive a full 30-minute private one-to-one meeting with the panelist of their choice.

The program topics cover pressing issues for industry insiders, from spotlight panels covering innovative partnerships in field of immunotherapy, pre-competitive collaborations, emerging markets and global drug development strategies, to a discussion on best deal structures. The business development track includes pharma/venture hybrid funds, financing models and a critical review of major deals of the past year.

Again this year, BioPharm America will celebrate the announcement of the Fierce 15, selected for their pioneering technology and innovative business models, with, Editor-in-Chief of FierceBiotech, set to lead a discussion with several Fierce 15 CEOs on the current landscape in life sciences.

The full program can be viewed online at .

Registration information for BioPharm America can be found by going to .

BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.

Additional links and information:

Follow BioPharm America 2012 on Twitter: (hashtag: #BPA12)

MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and healthcare, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

EBD Group’s sophisticated web-based partnering service, , is also used as the partnering engine at numerous third-party events around the world, and is the open online community of life science dealmakers that enhances partnering experiences all year long.

Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.